SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sesen Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 18, 2021 - SESN
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sesen Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 18, 2021 - SESN
New York, New York--(Newsfile Corp. - September 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:
紐約，紐約-(Newsfile Corp.-2021年9月24日)-Levi&Korsinsky，LLP發佈以下聲明：
To: All persons or entities who purchased or otherwise acquired securities of Sesen Bio, Inc. ("Sesen Bio") (NASDAQ: SESN) between December 21, 2020 and August 17, 2021 . You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:
致：購買或以其他方式獲得以下證券的所有個人或實體賽森生物公司(SESEN Bio，Inc.) (“SESEN Bio”)(納斯達克股票代碼：SESN)在2020年12月21日至2021年8月17日之間.特此通知您美國紐約南區地區法院已經開始提起證券集體訴訟。要獲取更多信息，請訪問：
https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19869&wire=5
Https://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19869&wire=5
or contact Joseph E. Levi, Esq. either via email atjlevi@levikorsinsky.comor by telephone at (212) 363-7500. There is no cost or obligation to you.
或聯繫約瑟夫·E·利維(Joseph E.Levi，Esq.)通過電子郵件atjlevi@levikorsinsky.com或電話(212)363-7500。對你來説沒有任何費用或義務。
Sesen Bio, Inc. NEWS - SESN NEWS
SESEN Bio，Inc.新聞-SESN新聞
CASE DETAILS: According to the filed complaint: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
案例詳細信息：根據起訴書：(1)Sesen Bio的癌症治療產品Vicineum的臨牀試驗有2000多項違反試驗方案的行為，其中215項被歸類為“重大”；(2)Sesen Bio的三名臨牀調查人員被發現犯有“嚴重違規行為”，包括“回溯數據”；(3)Sesen Bio提交了與Vicineum的生物製品許可證申請(“BLA”)有關的受污染數據；(4)SESEN Bio公司的臨牀試驗顯示，Vicineum泄漏到體內，導致包括肝功能衰竭和肝臟毒性在內的副作用，並增加致命性、藥物性肝損傷的風險；(5)由於上述原因，本公司關於Vicineum的BLA不太可能獲得批准；(6)由於上述原因，SESEN Bio公司很有可能需要進行額外的試驗以支持Vicineum的療效和安全性；(4)由於上述原因，SESEN Bio公司很有可能需要進行額外的試驗以支持Vicineum的療效和安全性；(6)由於上述原因，SESEN Bio公司很有可能需要進行額外的試驗以支持Vicineum的療效和安全性；(七)因上述原因，被告對公司業務、經營和前景的正面陳述具有重大誤導性和/或缺乏合理依據。
WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Sesen Bio, you have until October 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
這對股東意味着什麼：如果您在SESEN Bio中遭受損失，您必須在2021年10月18日請求法庭任命你為主要原告。你分享任何賠償的能力並不需要你擔任主要原告。
NO COST TO YOU: If you purchased Sesen Bio securities between December 21, 2020 and August 17, 2021, you may be entitled to compensation without payment of any out-of-pocket costs or fees.
您無需支付任何費用：如果您在2020年12月21日至2021年8月17日期間購買了SESEN Bio證券，您可能有權獲得賠償，而無需支付任何自掏腰包的成本或費用。
PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission formhttps://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19869&wire=5or call 212-363-7500 to discuss the case with Joseph E. Levi, Esq.
保護您的財務利益：請完成此簡短提交，formhttps://www.zlk.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=19869&wire=5or電話212-363-7500，與Esq的Joseph E.Levi討論此案。
WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by corporations.
為什麼是Levi&Korsinsky：Levi&Korsinsky在20年的時間裏為股東贏得了價值數億美元的官司，這是經過證明的記錄。我們代表併為那些被公司冤枉的股東而奮鬥。
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky, have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 80 employees, is committed to fostering, cultivating and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.
Levi&Korsinsky是一家全國公認的公司，在紐約、加利福尼亞州、康涅狄格州和華盛頓特區設有辦事處。該公司的創始合夥人約瑟夫·利維和愛德華·科辛斯基近20年來一直代表股東和機構客户，為美國和國際客户取得了令人矚目的成績。該公司擁有80多名員工，致力於為員工和我們所代表的員工培養、培育和維護多元化、公平和包容的文化。我們的律師擁有在證券訴訟中代表投資者的廣泛專業知識，並有在案件中追回數億美元的記錄。Levi&Korsinsky連續7年在機構股東服務(ISS)SCAS TOP 50報告中被評為美國頂級證券訴訟公司。SCAS的50強報告確定了美國頂級原告的證券律師事務所，ISS年復一年地承認Levi&Korsinsky是證券集體訴訟領域的領先律師事務所。
CONTACT:
聯繫方式：
Levi & Korsinsky, LLP
Levi&Korsinsky，LLP
Joseph E. Levi, Esq.
約瑟夫·E·利維(Joseph E.Levi)，Esq.
Ed Korsinsky, Esq.
埃德·科辛斯基(Ed Korsinsky)，Esq.
55 Broadway, 10th Floor
百老匯55號，10樓
New York, NY 10006
紐約州紐約市，郵編：10006
jlevi@levikorsinsky.com
郵箱：jlevi@levikorsinsky.com
Tel: (212) 363-7500
電話：(212)363-7500
Fax: (212) 363-7171
傳真：(212)363-7171
www.zlk.com
Www.zlk.com
To view the source version of this press release, please visithttps://www.newsfilecorp.com/release/97640
要查看本新聞稿的源版本，請訪問visithttps://www.newsfilecorp.com/release/97640
COMTEX_393968944/2523/2021-09-24T20:11:21
COMEX_393968944/2523/2021-09-24T20：11：21
譯文內容由第三人軟體翻譯。